Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

25P - RC48-ADC for metastatic salivary duct carcinoma with HER2-expression: A single-center retrospective study

Date

21 Mar 2023

Session

Poster display session

Presenters

Jun Cao

Citation

Annals of Oncology (2023) 8 (1suppl_3): 101023-101023. 10.1016/esmoop/esmoop101023

Authors

J. Cao, Q. Ji

Author affiliations

  • Medical Oncology Department, Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, 310022 - Hangzhou/CN

Resources

This content is available to ESMO members and event participants.

Abstract 25P

Background

Agent targeting HER2 is promising and is the best studied therapy in patients with HER2-positive salivary duct carcinoma (SDC). RC48-ADC (Disitamab Vedotin) is a novel humanized anti-HER2 antibody-drug conjugate (ADC). But the efficacy and safety of RC48-ADC is still unknown in metastatic SDC with HER2-positive.

Methods

Eligible patients from Zhejiang Cancer Hospital were 35∼76 years old, with confirmed, histologically HER2-expression (IHC1+, 2+, 3+), metastatic SDC. Patients had at least one line of systemic chemotherapy. Patients received RC48-ADC at 1.5 or 2 mg/kg, every two weeks. Clinical efficacy and safety were assessed.

Results

This study enrolled HER2-expression metastatic SDC patients from June 2022 to Dec 2022. 10 mSDC patients (8 males, 2 females) were enrolled. 90% patients had received ≥2 lines systemic chemotherapy. 80% patients had visceral metastases. As of 05 Jan 2023 (data cutoff), 1 patient received CR, 4 patients received PR, 4 patients received SD, and only 1 patient received PD. The overall confirmed DCR was 90%. Most common treatment-related AEs were hypoaesthesia (70%), asthenia (60%), Leukopenia (30%), decreased appetite (20%), alopecia (10%). The grade≥3 TRAEs only included hypoaesthesia (30.0%) and neutropenia (10%).

Conclusions

RC48-ADC showed continuously a promising efficacy with a manageable safety profile in HER2-expression mSDC patients who had failed at least one line systemic chemotherapy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.